TCGA-92-8064-01A-11R-2247-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 58
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-77-8136-01A-11R-2247-07 | — | cohortSQ1 | 0.882 |
| 2 | MNG1210 | — | — | 0.853 |
| 3 | TCGA-LC-A66R-01A-41R-A30C-07 | — | — | 0.848 |
| 4 | TCGA-A7-A4SD-01A-11R-A266-07 | — | E | 0.829 |
| 5 | TCGA-XF-A9SM-01A-11R-A42T-07 | — | — | 0.826 |
| 6 | TCGA-A2-A0CM-01A-31R-A034-07 | — | E | 0.824 |
| 7 | TCGA-FD-A3B3-01A-12R-A206-07 | — | — | 0.822 |
| 8 | TCGA-XF-A9SY-01A-21R-A42T-07 | — | — | 0.822 |
| 9 | SRR934956 | — | — | 0.820 |
| 10 | TCGA-CR-7373-01A-11R-2016-07 | — | — | 0.819 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.610 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.580 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.540 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.490 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.440 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.410 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.390 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.380 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.350 | Temsirolimus | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.300 | Idelalisib | — uncovered |
| APOPTOSIS | 0.290 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.290 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.270 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.260 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.250 | Inavolisib | — uncovered |
| COMPLEMENT | 0.240 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.240 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.230 | Idelalisib | — uncovered |